Matt Hagood

Matt Hagood is an experienced equity research associate specializing in biotechnology with a career spanning various prestigious firms. Currently at UBS since September 2025, Matt focuses on biotech equity research. Prior experience includes a role at Jefferies from July 2024 to August 2025 and a position as an associate at Casdin Capital, LLC from November 2023 to April 2024. Previously, Matt worked at Oppenheimer & Co. Inc. from June 2021 to November 2023 as an equity research associate and biotechnology equity research intern. Matt began a career in research as an undergraduate researcher at the University of Virginia, where projects included data analysis and presentation related to multi-drug targeted therapies for Head and Neck Squamous Cell Carcinoma. Matt holds a Master of Arts in Biotechnology from Columbia University and a Bachelor of Science in Biochemistry from the University of Virginia.